Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

Journal of Medicinal Chemistry

Volumn 59, Issue 5, 2016, Pages 1946-1959

  Plano, Daniel ^b   Karelia, Deepkamal N ^a   Pandey, Manoj K ^a   Spallholz, Julian E ^c   Amin, Shantu ^a   Sharma, Arun K ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 ACETOXYBENZAMIDO) 3 (METHYLSELENYL)PROPANOIC ACID; 2 (4 ISOBUTYLPHENYL) N (2 SELENOCYANATOETHYL)PROPANAMIDE; 2 (6 METHOXY 2 NAPHTHYL) N (2 SELENOCYANATOETHYL)PROPANAMIDE; 2 SELENOCYANATOETHYL 2 ACETOXYBENZOATE; 2 [(2 BROMOETHYL)CARBAMOYL]PHENYL ACETATE; 2 [(2 SELENOCYANATOETHYL)CARBAMOYL]PHENYL ACETATE; 2 [(2 THIOCYANATOETHYL)CARBAMOYL]PHENYL ACETATE; 2 [[(2 BROMOETHYL)SELENYL]CARBONYL]PHENYL ACETATE; 2 [[(2 SELENOCYANATOETHYL)SELENYL]CARBONYL]PHENYL ACETATE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CASPASE 3; CASPASE 7; CYCLIN B1; CYCLIN E; CYCLIN E1; CYTOTOXIC AGENT; FLUOROURACIL; IBUPROFEN DERIVATIVE; NAPROXEN DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOSELENIUM DERIVATIVE; PROTEIN P21; REACTIVE OXYGEN METABOLITE; SELENOCOXIB 1; UNCLASSIFIED DRUG; [[ETHANE 1,2 DIYLBIS(SELANEDIYL)]BIS(CARBONYL)]BIS(2,1 PHENYLENE)DIACETATE; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ELIMINATION REACTION; EMBRYO; ENZYME ACTIVATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOPHILICITY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; SYNTHESIS; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; ORGANOSELENIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960920207     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01503     Document Type: Article

References (77)

1. Dube, C.; Rostom, A.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D.; Force, U. S. P. S. T. The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force Ann. Intern. Med. 2007, 146, 365-375 10.7326/0003-4819-146-5-200703060-00009
2. Rostom, A.; Dube, C.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.; Sampson, M.; Moher, D.; Force, U. S. P. S. T. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force Ann. Intern. Med. 2007, 146, 376-389 10.7326/0003-4819-146-5-200703060-00010
3. Cole, B. F.; Logan, R. F.; Halabi, S.; Benamouzig, R.; Sandler, R. S.; Grainge, M. J.; Chaussade, S.; Baron, J. A. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials J. Natl. Cancer Inst 2009, 101, 256-266 10.1093/jnci/djn485
4. Flossmann, E.; Rothwell, P. M.; British Doctors Aspirin, T.; the, U. K. T. I. A. A. T. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies Lancet 2007, 369, 1603-1613 10.1016/S0140-6736(07)60747-8
5. Algra, A. M.; Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol. 2012, 13, 518-527 10.1016/S1470-2045(12)70112-2
6. Rothwell, P. M. Aspirin in prevention of sporadic colorectal cancer: Current clinical evidence and overall balance of risks and benefits Recent Results Cancer Res. 2013, 191, 121-142 10.1007/978-3-642-30331-9
7. Rothwell, P. M.; Price, J. F.; Fowkes, F. G.; Zanchetti, A.; Roncaglioni, M. C.; Tognoni, G.; Lee, R.; Belch, J. F.; Wilson, M.; Mehta, Z.; Meade, T. W. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 2012, 379, 1602-1612 10.1016/S0140-6736(11)61720-0
8. Rothwell, P. M.; Wilson, M.; Elwin, C. E.; Norrving, B.; Algra, A.; Warlow, C. P.; Meade, T. W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 2010, 376, 1741-1750 10.1016/S0140-6736(10)61543-7
9. Chan, A. T.; Manson, J. E.; Feskanich, D.; Stampfer, M. J.; Colditz, G. A.; Fuchs, C. S. Long-term aspirin use and mortality in women Arch. Intern. Med. 2007, 167, 562-572 10.1001/archinte.167.6.562
10. Agrawal, A.; Fentiman, I. S. NSAIDs and breast cancer: A possible prevention and treatment strategy Int. J. Clin Pract 2008, 62, 444-449 10.1111/j.1742-1241.2007.01668.x
11. Johannesdottir, S. A.; Chang, E. T.; Mehnert, F.; Schmidt, M.; Olesen, A. B.; Sorensen, H. T. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: A population-based case-control study Cancer 2012, 118, 4768-4776 10.1002/cncr.27406
12. Seshasai, S. R.; Wijesuriya, S.; Sivakumaran, R.; Nethercott, S.; Erqou, S.; Sattar, N.; Ray, K. K. Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials Arch. Intern. Med. 2012, 172, 209-216 10.1001/archinternmed.2011.628
13. Trabert, B.; Ness, R. B.; Lo-Ciganic, W. H.; Murphy, M. A.; Goode, E. L.; Poole, E. M.; Brinton, L. A.; Webb, P. M.; Nagle, C. M.; Jordan, S. J.; Australian Ovarian Cancer Study Group, A. C. S.; Risch, H. A.; Rossing, M. A.; Doherty, J. A.; Goodman, M. T.; Lurie, G.; Kjaer, S. K.; Hogdall, E.; Jensen, A.; Cramer, D. W.; Terry, K. L.; Vitonis, A.; Bandera, E. V.; Olson, S.; King, M. G.; Chandran, U.; Anton-Culver, H.; Ziogas, A.; Menon, U.; Gayther, S. A.; Ramus, S. J.; Gentry-Maharaj, A.; Wu, A. H.; Pearce, C. L.; Pike, M. C.; Berchuck, A.; Schildkraut, J. M.; Wentzensen, N. Ovarian Cancer Association, C. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium J. Natl. Cancer Inst 2014, 106, djt431 10.1093/jnci/djt431
14. Cuzick, J.; Otto, F.; Baron, J. A.; Brown, P. H.; Burn, J.; Greenwald, P.; Jankowski, J.; La Vecchia, C.; Meyskens, F.; Senn, H. J.; Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement Lancet Oncol. 2009, 10, 501-507 10.1016/S1470-2045(09)70035-X
15. Burn, J.; Gerdes, A. M.; Macrae, F.; Mecklin, J. P.; Moeslein, G.; Olschwang, S.; Eccles, D.; Evans, D. G.; Maher, E. R.; Bertario, L.; Bisgaard, M. L.; Dunlop, M. G.; Ho, J. W.; Hodgson, S. V.; Lindblom, A.; Lubinski, J.; Morrison, P. J.; Murday, V.; Ramesar, R.; Side, L.; Scott, R. J.; Thomas, H. J.; Vasen, H. F.; Barker, G.; Crawford, G.; Elliott, F.; Movahedi, M.; Pylvanainen, K.; Wijnen, J. T.; Fodde, R.; Lynch, H. T.; Mathers, J. C.; Bishop, D. T. Investigators, C. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial Lancet 2011, 378, 2081-2087 10.1016/S0140-6736(11)61049-0
16. Hawk, E. T.; Levin, B. Colorectal cancer prevention J. Clin. Oncol. 2005, 23, 378-391 10.1200/JCO.2005.08.097
17. Ulrich, C. M.; Bigler, J.; Potter, J. D. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics Nat. Rev. Cancer 2006, 6, 130-140 10.1038/nrc1801
18. Shureiqi, I.; Chen, D.; Lee, J. J.; Yang, P.; Newman, R. A.; Brenner, D. E.; Lotan, R.; Fischer, S. M.; Lippman, S. M. 15-LOX-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells J. Natl. Cancer Inst 2000, 92, 1136-1142 10.1093/jnci/92.14.1136
19. Qiu, W.; Wang, X.; Leibowitz, B.; Liu, H.; Barker, N.; Okada, H.; Oue, N.; Yasui, W.; Clevers, H.; Schoen, R. E.; Yu, J.; Zhang, L. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20027-20032 10.1073/pnas.1010430107
20. Jones, M. K.; Wang, H.; Peskar, B. M.; Levin, E.; Itani, R. M.; Sarfeh, I. J.; Tarnawski, A. S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing Nat. Med. 1999, 5, 1418-1423 10.1038/70995
21. Yamamoto, Y.; Yin, M. J.; Lin, K. M.; Gaynor, R. B. Sulindac inhibits activation of the NF-kappaB pathway J. Biol. Chem. 1999, 274, 27307-27314 10.1074/jbc.274.38.27307
22. Stark, L. A.; Din, F. V.; Zwacka, R. M.; Dunlop, M. G. Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells FASEB J. 2001, 15, 1273-1275 10.1096/fj.00-0529fje
23. Slattery, M. L.; Samowitz, W.; Hoffman, M.; Ma, K. N.; Levin, T. R.; Neuhausen, S. Aspirin, NSAIDs, and colorectal cancer: Possible involvement in an insulin-related pathway Cancer Epidemiol Biomarkers Prev 2004, 13, 538-545
24. Din, F. V.; Valanciute, A.; Houde, V. P.; Zibrova, D.; Green, K. A.; Sakamoto, K.; Alessi, D. R.; Dunlop, M. G. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells Gastroenterology 2012, 142, 1504-1515.e3 10.1053/j.gastro.2012.02.050
25. Steinberg, G. R.; Dandapani, M.; Hardie, D. G. AMPK: Mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol. Metab. 2013, 24, 481-487 10.1016/j.tem.2013.06.002
26. Bansal, Y.; Silakari, O. Synthesis and pharmacological evaluation of polyfunctional benzimidazole-NSAID chimeric molecules combining anti-inflammatory, immunomodulatory and antioxidant activities Arch. Pharmacal Res. 2014, 37, 1426-1436 10.1007/s12272-013-0282-4
27. Uzgoren-Baran, A.; Tel, B. C.; Sarigol, D.; Ozturk, E. I.; Kazkayasi, I.; Okay, G.; Ertan, M.; Tozkoparan, B. Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one substituted with ibuprofen: Novel non-steroidal anti-inflammatory agents with favorable gastrointestinal tolerance Eur. J. Med. Chem. 2012, 57, 398-406 10.1016/j.ejmech.2012.07.009
28. Basudhar, D.; Bharadwaj, G.; Cheng, R. Y.; Jain, S.; Shi, S.; Heinecke, J. L.; Holland, R. J.; Ridnour, L. A.; Caceres, V. M.; Spadari-Bratfisch, R. C.; Paolocci, N.; Velazquez-Martinez, C. A.; Wink, D. A.; Miranda, K. M. Synthesis and chemical and biological comparison of nitroxyl- A nd nitric oxide-releasing diazeniumdiolate-based aspirin derivatives J. Med. Chem. 2013, 56, 7804-7820 10.1021/jm400196q
29. Huang, Z.; Velazquez, C. A.; Abdellatif, K. R.; Chowdhury, M. A.; Reisz, J. A.; DuMond, J. F.; King, S. B.; Knaus, E. E. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): Synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies J. Med. Chem. 2011, 54, 1356-1364 10.1021/jm101403g
30. Kozoni, V.; Rosenberg, T.; Rigas, B. Development of novel agents based on nitric oxide for the control of colon cancer Acta Pharmacol. Sin. 2007, 28, 1429-1433 10.1111/j.1745-7254.2007.00696.x
31. Rao, C. V.; Reddy, B. S.; Steele, V. E.; Wang, C. X.; Liu, X.; Ouyang, N.; Patlolla, J. M.; Simi, B.; Kopelovich, L.; Rigas, B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: Effects on molecular targets Mol. Cancer Ther. 2006, 5, 1530-1538 10.1158/1535-7163.MCT-06-0061
32. Williams, J. L.; Borgo, S.; Hasan, I.; Castillo, E.; Traganos, F.; Rigas, B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention Cancer Res. 2001, 61, 3285-3289
33. Williams, J. L.; Nath, N.; Chen, J.; Hundley, T. R.; Gao, J.; Kopelovich, L.; Kashfi, K.; Rigas, B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: Implications for chemoprevention Cancer Res. 2003, 63, 7613-7618
34. Fiorucci, S.; Orlandi, S.; Mencarelli, A.; Caliendo, G.; Santagada, V.; Distrutti, E.; Santucci, L.; Cirino, G.; Wallace, J. L. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis Br. J. Pharmacol. 2007, 150, 996-1002 10.1038/sj.bjp.0707193
35. Li, L.; Rossoni, G.; Sparatore, A.; Lee, L. C.; Del Soldato, P.; Moore, P. K. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative Free Radical Biol. Med. 2007, 42, 706-719 10.1016/j.freeradbiomed.2006.12.011
36. Wallace, J. L.; Caliendo, G.; Santagada, V.; Cirino, G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346) Br. J. Pharmacol. 2010, 159, 1236-1246 10.1111/j.1476-5381.2009.00611.x
37. Wallace, J. L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat Gastroenterology 2007, 132, 261-271 10.1053/j.gastro.2006.11.042
38. Chattopadhyay, M.; Kodela, R.; Nath, N.; Barsegian, A.; Boring, D.; Kashfi, K. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo Biochem. Pharmacol. 2012, 83, 723-732 10.1016/j.bcp.2011.12.019
39. Chattopadhyay, M.; Kodela, R.; Nath, N.; Dastagirzada, Y. M.; Velazquez-Martinez, C. A.; Boring, D.; Kashfi, K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect Biochem. Pharmacol. 2012, 83, 715-722 10.1016/j.bcp.2011.12.018
40. Chattopadhyay, M.; Kodela, R.; Nath, N.; Street, C. R.; Velazquez-Martinez, C. A.; Boring, D.; Kashfi, K. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo Biochem. Pharmacol. 2012, 83, 733-740 10.1016/j.bcp.2011.12.020
41. Chattopadhyay, M.; Kodela, R.; Olson, K. R.; Kashfi, K. NOSH-aspirin (NBS-1120), a novel nitric oxide- A nd hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model Biochem. Biophys. Res. Commun. 2012, 419, 523-528 10.1016/j.bbrc.2012.02.051
42. Kodela, R.; Chattopadhyay, M.; Kashfi, K. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals ACS Med. Chem. Lett. 2012, 3, 257-262 10.1021/ml300002m
43. Huang, L.; Mackenzie, G. G.; Sun, Y.; Ouyang, N.; Xie, G.; Vrankova, K.; Komninou, D.; Rigas, B. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds Cancer Res. 2011, 71, 7617-7627 10.1158/0008-5472.CAN-11-2349
44. Ouyang, N.; Ji, P.; Williams, J. L. A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats Int. J. Oncol. 2013, 42, 643-650 10.3892/ijo.2012.1756
45. Vinceti, M.; Crespi, C. M.; Malagoli, C.; Del Giovane, C.; Krogh, V. Friend or foe? The current epidemiologic evidence on selenium and human cancer risk J. Environ. Sci. Health C Environ. Carcinog Ecotoxicol Rev. 2013, 31, 305-341 10.1080/10590501.2013.844757
46. Sharma, A. K.; Amin, S. Post SELECT: Selenium on trial Future Med. Chem. 2013, 5, 163-174 10.4155/fmc.12.203
47. Chung, C. Y.; Madhunapantula, S. V.; Desai, D.; Amin, S.; Robertson, G. P. Melanoma prevention using topical PBISe Cancer Prev. Res. 2011, 4, 935-948 10.1158/1940-6207.CAPR-10-0202
48. Lin, T.; Ding, Z.; Li, N.; Xu, J.; Luo, G.; Liu, J.; Shen, J. Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-kappaB suppression Eur. J. Cancer 2011, 47, 1890-1907 10.1016/j.ejca.2011.04.004
49. Nguyen, N.; Sharma, A.; Nguyen, N.; Sharma, A. K.; Desai, D.; Huh, S. J.; Amin, S.; Meyers, C.; Robertson, G. P. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4 Cancer Prev. Res. 2011, 4, 248-258 10.1158/1940-6207.CAPR-10-0106
50. Yang, Y.; Huang, F.; Ren, Y.; Xing, L.; Wu, Y.; Li, Z.; Pan, H.; Xu, C. The anticancer effects of sodium selenite and selenomethionine on human colorectal carcinoma cell lines in nude mice Oncol. Res. 2009, 18, 1-8 10.3727/096504009789745647
51. Zeng, H.; Cheng, W. H.; Johnson, L. K. Methylselenol, a selenium metabolite, modulates p53 pathway and inhibits the growth of colon cancer xenografts in Balb/c mice J. Nutr. Biochem. 2013, 24, 776-780 10.1016/j.jnutbio.2012.04.008
52. Bhattacharya, A. Methylselenocysteine: A promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs Expert Opin. Drug Delivery 2011, 8, 749-763 10.1517/17425247.2011.571672
53. Chintala, S.; Toth, K.; Cao, S.; Durrani, F. A.; Vaughan, M. M.; Jensen, R. L.; Rustum, Y. M. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha Cancer Chemother. Pharmacol. 2010, 66, 899-911 10.1007/s00280-009-1238-8
54. Li, Z.; Carrier, L.; Belame, A.; Thiyagarajah, A.; Salvo, V. A.; Burow, M. E.; Rowan, B. G. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis Breast Cancer Res. Treat. 2009, 118, 33-43 10.1007/s10549-008-0216-x
55. Martins, I. L.; Miranda, J. P.; Oliveira, N. G.; Fernandes, A. S.; Goncalves, S.; Antunes, A. M. Synthesis and biological activity of 6-selenocaffeine: Potential modulator of chemotherapeutic drugs in breast cancer cells Molecules 2013, 18, 5251-5264 10.3390/molecules18055251
56. Qi, Y.; Fu, X.; Xiong, Z.; Zhang, H.; Hill, S. M.; Rowan, B. G.; Dong, Y. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer PLoS One 2012, 7, e31539 10.1371/journal.pone.0031539
57. Gowda, R.; Madhunapantula, S. V.; Desai, D.; Amin, S.; Robertson, G. P. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma Mol. Cancer Ther. 2013, 12, 3-15 10.1158/1535-7163.MCT-12-0492
58. Sanmartin, C.; Plano, D.; Palop, J. A. Selenium compounds and apoptotic modulation: A new perspective in cancer therapy Mini-Rev. Med. Chem. 2008, 8, 1020-1031 10.2174/138955708785740625
59. Sanmartin, C.; Plano, D.; Sharma, A. K.; Palop, J. A. Selenium compounds, apoptosis and other types of cell death: An overview for cancer therapy Int. J. Mol. Sci. 2012, 13, 9649-9672 10.3390/ijms13089649
60. Desai, D.; Kaushal, N.; Gandhi, U. H.; Arner, R. J.; D'Souza, C.; Chen, G.; Vunta, H.; El-Bayoumy, K.; Amin, S.; Prabhu, K. S. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib Chem.-Biol. Interact. 2010, 188, 446-456 10.1016/j.cbi.2010.09.021
61. Desai, D.; Sinha, I.; Null, K.; Wolter, W.; Suckow, M. A.; King, T.; Amin, S.; Sinha, R. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells Int. J. Cancer 2010, 127, 230-238 10.1002/ijc.25033
62. Abbas, A. M.; Sakr, H. F. Effect of selenium and grape seed extract on indomethacin-induced gastric ulcers in rats J. Physiol. Biochem. 2013, 69, 527-537 10.1007/s13105-013-0241-z
63. Bi, X.; Pohl, N.; Dong, H.; Yang, W. Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice J. Hematol. Oncol. 2013, 6, 8 10.1186/1756-8722-6-8
64. Pathi, S.; Jutooru, I.; Chadalapaka, G.; Nair, V.; Lee, S. O.; Safe, S. Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors PLoS One 2012, 7, e48208 10.1371/journal.pone.0048208
65. Sostres, C.; Gargallo, C. J.; Lanas, A. Aspirin, cyclooxygenase inhibition and colorectal cancer World J. Gastrointest. Pharmacol. Ther. 2014, 5, 40-49 10.4292/wjgpt.v5.i1.40
66. Cao, S.; Durrani, F. A.; Toth, K.; Rustum, Y. M. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models Br. J. Cancer 2014, 110, 1733-1743 10.1038/bjc.2014.85
67. Fang, M.; Guo, W. R.; Park, Y.; Kang, H. G.; Zarbl, H. Enhancement of NAD+-dependent SIRT1 deacetylase activity by methylselenocysteine resets the circadian clock in carcinogen-treated mammary epithelial cells Oncotarget 2015, 6, 42879-42891 10.18632/oncotarget.6002
68. Kim, T.; Jung, U.; Cho, D. Y.; Chung, A. S. Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells Carcinogenesis 2001, 22, 559-565 10.1093/carcin/22.4.559
69. Sanmartin, C.; Plano, D.; Dominguez, E.; Font, M.; Calvo, A.; Prior, C.; Encio, I.; Palop, J. A. Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents Molecules 2009, 14, 3313-3338 10.3390/molecules14093313
70. Cayrol, C.; Knibiehler, M.; Ducommun, B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells Oncogene 1998, 16, 311-320 10.1038/sj.onc.1201543
71. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E. S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade Cell 1997, 91, 479-489 10.1016/S0092-8674(00)80434-1
72. Misra, S.; Boylan, M.; Selvam, A.; Spallholz, J. E.; Bjornstedt, M. Redox-active selenium compounds - from toxicity and cell death to cancer treatment Nutrients 2015, 7, 3536-3556 10.3390/nu7053536
73. Saleh, A. M.; Aljada, A.; El-Abadelah, M. M.; Sabri, S. S.; Zahra, J. A.; Nasr, A.; Aziz, M. A. The pyridone-annelated isoindigo (5′-Cl) induces apoptosis, dysregulation of mitochondria and formation of ROS in leukemic HL-60 cells Cell. Physiol. Biochem. 2015, 35, 1958-1974 10.1159/000374004
74. Huang, E. S.; Strate, L. L.; Ho, W. W.; Lee, S. S.; Chan, A. T. Long-term use of aspirin and the risk of gastrointestinal bleeding Am. J. Med. 2011, 124, 426-433 10.1016/j.amjmed.2010.12.022
75. Pandey, M. K.; Gowda, K.; Doi, K.; Sharma, A. K.; Wang, H. G.; Amin, S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells PLoS One 2013, 8, e78570 10.1371/journal.pone.0078570
76. Darzynkiewicz, Z.; Juan, G.; Bedner, E. Determining cell cycle stages by flow cytometry. Current Protocols in Cell Biology; Wiley: Hoboken, NJ, 2001; Chapter 8, Unit 8.4. 10.1002/0471143030.cb0804s01
77. Pandey, M. K.; Kale, V. P.; Song, C.; Sung, S. S.; Sharma, A. K.; Talamo, G.; Dovat, S.; Amin, S. G. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways Exp. Hematol. 2014, 42, 883-896 10.1016/j.exphem.2014.07.261